-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor’s note iNature is China’s largest academic public account.
It is jointly created by a team of doctors from Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature talent public account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us
.
iNature intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver malignancy
.
In the next 20 to 30 years, the incidence of iCCA is expected to increase 10 times globally, but treatment strategies are still limited
.
Most patients are usually diagnosed at an advanced stage, when the available systemic treatments are limited
.
Therefore, there is an urgent need for a deeper understanding of the pathogenesis of iCCA to facilitate the determination of suitable therapeutic targets
.
On December 30, 2021, Jia Fan, Gao Qiang, Fudan University, Zhou Hu, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Gao Daming, the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, published a joint communication online in Cancer Cell entitled "Proteogenomic characterization identifies clinically relevant subgroups of" Intrahepatic cholangiocarcinoma" research paper, which used paired tumors and adjacent liver tissues from 262 patients to perform protegenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
.
Comprehensive protein genomics analysis prioritizes genetic aberrations and reveals signs of iCCA pathogenesis
.
The characteristics of aflatoxin are related to tumorigenesis, proliferation and immunosuppression
.
Mutation-related signal analysis indicates that co-mutation of TP53 and KRAS may promote iCCA transfer through the integrin-FAK-SRC pathway
.
FGFR2 fusion activates the Rho GTPase pathway, which may be a potential source of new antigens
.
Proteomics analysis identified four patient subgroups (S1-S4) with subgroup-specific biomarkers
.
These proteomics subgroups have different characteristics in terms of prognosis, genetic changes, microenvironment disorders, tumor microbiota composition, and potential treatments
.
SLC16A3 and HKDC1 were further identified as potential prognostic biomarkers related to metabolic reprogramming of iCCA cells
.
This study provides a valuable resource for researchers and clinicians to further determine the molecular pathogenesis and treatment opportunities of iCCA
.
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver malignancy
.
In the next 20 to 30 years, the incidence of iCCA is expected to increase 10 times globally, but treatment strategies are still limited
.
Most patients are usually diagnosed at an advanced stage, when the available systemic treatments are limited
.
Therefore, there is an urgent need for a deeper understanding of the pathogenesis of iCCA to facilitate the determination of suitable therapeutic targets
.
The latest advances in genome and transcriptome sequencing analysis reveal the genetic landscape of iCCA
.
Therefore, precision medicine developed for promising molecular targets (including FGFR2 inhibitors and IDH1/IDH2 inhibitors) is becoming a reality
.
At the same time, multi-dimensional "omics" strategies including proteomics and phosphoproteomics analysis and genomic analysis have clarified new disease subtypes and signaling pathways, and discovered potential targets for the development of treatments for other cancer types
.
This multi-omics strategy may help reveal new mechanisms and determine new goals for developing therapies, thereby providing additional treatment options for iCCA patients
.
Article pattern diagram (picture from Cancer Cell) To this end, with the support of the International Cancer Proteome Consortium, the study conducted comprehensive genome, transcriptome, proteome, phosphoproteome, and microbiome analysis on 262 Chinese iCCA patients
.
Basic data is an important resource for further biology, diagnosis, and drug discovery
.
The comprehensive protein genomics analysis of the study shows that genetic changes may cause phenotypic disturbances and reveal subgroups of diseases with different characteristics and prognosis, thereby delineating the complex mechanism of iCCA pathogenesis for prospective exploration of precise management
.
Academician Fan Jia of Zhongshan Hospital Affiliated to Fudan University, Researcher Zhou Hu of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Researcher Gao Daming of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, and Professor Gao Qiang of Zhongshan Hospital Affiliated to Fudan University are the co-corresponding authors of this article
.
Dr.
Dong Liangqing, Zhongshan Hospital Affiliated to Fudan University, Lu Dayun, Ph.
D.
candidate at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Chen Ran, Ph.
D.
candidate at the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Lin Youpei, Ph.
D.
Dr.
Zhu Hongwen, Dr.
Zhang Zhou from Burning Rock Medical and Dr.
Cai Shangli are the co-first authors of this article
.
This work was supported by He Fuchu, Academician of the National Center for Protein Science (Beijing), Dr.
Henry Rodriguez of the National Cancer Institute, Professor Zhang Bing of the Baylor College of Medicine, Professor Daniel Figeys of the University of Ottawa, Canada, Professor Li Ding of the University of Washington Institute of Genetics, Mount Sinai, USA Strong support from Professor Pei Wang from Icahn School of Medicine
.
Reference message: https://
It is jointly created by a team of doctors from Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature talent public account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us
.
iNature intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver malignancy
.
In the next 20 to 30 years, the incidence of iCCA is expected to increase 10 times globally, but treatment strategies are still limited
.
Most patients are usually diagnosed at an advanced stage, when the available systemic treatments are limited
.
Therefore, there is an urgent need for a deeper understanding of the pathogenesis of iCCA to facilitate the determination of suitable therapeutic targets
.
On December 30, 2021, Jia Fan, Gao Qiang, Fudan University, Zhou Hu, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Gao Daming, the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, published a joint communication online in Cancer Cell entitled "Proteogenomic characterization identifies clinically relevant subgroups of" Intrahepatic cholangiocarcinoma" research paper, which used paired tumors and adjacent liver tissues from 262 patients to perform protegenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
.
Comprehensive protein genomics analysis prioritizes genetic aberrations and reveals signs of iCCA pathogenesis
.
The characteristics of aflatoxin are related to tumorigenesis, proliferation and immunosuppression
.
Mutation-related signal analysis indicates that co-mutation of TP53 and KRAS may promote iCCA transfer through the integrin-FAK-SRC pathway
.
FGFR2 fusion activates the Rho GTPase pathway, which may be a potential source of new antigens
.
Proteomics analysis identified four patient subgroups (S1-S4) with subgroup-specific biomarkers
.
These proteomics subgroups have different characteristics in terms of prognosis, genetic changes, microenvironment disorders, tumor microbiota composition, and potential treatments
.
SLC16A3 and HKDC1 were further identified as potential prognostic biomarkers related to metabolic reprogramming of iCCA cells
.
This study provides a valuable resource for researchers and clinicians to further determine the molecular pathogenesis and treatment opportunities of iCCA
.
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver malignancy
.
In the next 20 to 30 years, the incidence of iCCA is expected to increase 10 times globally, but treatment strategies are still limited
.
Most patients are usually diagnosed at an advanced stage, when the available systemic treatments are limited
.
Therefore, there is an urgent need for a deeper understanding of the pathogenesis of iCCA to facilitate the determination of suitable therapeutic targets
.
The latest advances in genome and transcriptome sequencing analysis reveal the genetic landscape of iCCA
.
Therefore, precision medicine developed for promising molecular targets (including FGFR2 inhibitors and IDH1/IDH2 inhibitors) is becoming a reality
.
At the same time, multi-dimensional "omics" strategies including proteomics and phosphoproteomics analysis and genomic analysis have clarified new disease subtypes and signaling pathways, and discovered potential targets for the development of treatments for other cancer types
.
This multi-omics strategy may help reveal new mechanisms and determine new goals for developing therapies, thereby providing additional treatment options for iCCA patients
.
Article pattern diagram (picture from Cancer Cell) To this end, with the support of the International Cancer Proteome Consortium, the study conducted comprehensive genome, transcriptome, proteome, phosphoproteome, and microbiome analysis on 262 Chinese iCCA patients
.
Basic data is an important resource for further biology, diagnosis, and drug discovery
.
The comprehensive protein genomics analysis of the study shows that genetic changes may cause phenotypic disturbances and reveal subgroups of diseases with different characteristics and prognosis, thereby delineating the complex mechanism of iCCA pathogenesis for prospective exploration of precise management
.
Academician Fan Jia of Zhongshan Hospital Affiliated to Fudan University, Researcher Zhou Hu of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Researcher Gao Daming of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, and Professor Gao Qiang of Zhongshan Hospital Affiliated to Fudan University are the co-corresponding authors of this article
.
Dr.
Dong Liangqing, Zhongshan Hospital Affiliated to Fudan University, Lu Dayun, Ph.
D.
candidate at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Chen Ran, Ph.
D.
candidate at the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Lin Youpei, Ph.
D.
Dr.
Zhu Hongwen, Dr.
Zhang Zhou from Burning Rock Medical and Dr.
Cai Shangli are the co-first authors of this article
.
This work was supported by He Fuchu, Academician of the National Center for Protein Science (Beijing), Dr.
Henry Rodriguez of the National Cancer Institute, Professor Zhang Bing of the Baylor College of Medicine, Professor Daniel Figeys of the University of Ottawa, Canada, Professor Li Ding of the University of Washington Institute of Genetics, Mount Sinai, USA Strong support from Professor Pei Wang from Icahn School of Medicine
.
Reference message: https://
